In the original article, the labelling of “Class 2” and “Class 3” isolates was switched erroneously in Table 2 and Figure 9B. The corrected Table 2 and Figure 9 appear below.
Table 2
| Class | Isolate number | Isolate, full name |
|---|---|---|
| 1 | – | MC58 |
| 1 | H44/76 | |
| 2 | M10_240684 | |
| 3 | M10_240701 | |
| 4 | M02_241729 | |
| 3 | 5 | M10_240579 |
| 6 | M13_240525 | |
| 7 | M04_241215 | |
| 8 | M11_241066 | |
| 9 | M13_240614 | |
| 2 | – | L91543 |
| 10 | M10_240750 | |
| 11 | M13_240675 | |
| 12 | M11_240236 | |
| 13 | M12_240006 | |
| 4 | 14 | M11_241033 |
| 15 | M14_240367 | |
| 16 | M02_240210 | |
| 17 | M11_240077 | |
| 18 | M13_240486 |
MenB invasive isolates used in this study.
The SP class is indicated for each isolate.
Figure 9
Further, the year the Trumenba vaccine was licensed is incorrectly provided as “2015” and should be “2014”.
A correction has been made to the Introduction, paragraph three.
“Through an accelerated approval process, both Trumemba (Pfizer) and Bexsero (GSK) were licensed by the FDA in 2014 and 2015 respectively for immunization to prevent invasive disease by meningococcal group B in the United States in individuals 10 to 25 years of age. Trumenba comprises two recombinant FHbps, one from subfamily A, the other from subfamily B, both containing the lipid moiety found in the native protein (Fletcher et al., 2004; Gandhi et al., 2016). A recombinant non-lipidated form of FHbp from subfamily B is also one of the antigens of the Bexsero vaccine (GSK) (Vernikos and Medini, 2014) licensed for infants from 2 months of age in Europe in 2013 and, like Trumenba, now licensed globally (Basta and Christensen, 2016).”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
meningoccocus, FHbp, vaccine, signal peptide, lipoprotein, Lnt, Slam
Citation
da Silva RAG, Karlyshev AV, Oldfield NJ, Wooldridge KG, Bayliss CD, Ryan A and Griffin R (2020) Corrigendum: Variant Signal Peptides of Vaccine Antigen, FHbp, Impair Processing Affecting Surface Localization and Antibody-Mediated Killing in Most Meningococcal Isolates. Front. Microbiol. 11:55. doi: 10.3389/fmicb.2020.00055
Received
10 January 2020
Accepted
13 January 2020
Published
05 February 2020
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2020
Updates
Copyright
© 2020 da Silva, Karlyshev, Oldfield, Wooldridge, Bayliss, Ryan and Griffin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ruth Griffin ruth.griffin1@nottingham.ac.uk
This article was submitted to Infectious Diseases, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.